Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Myo-Inositol wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
7 of 12 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Myo-Inositol and Semaglutide have evidence — compare verdict strength side-by-side.
2-4g daily for PCOS; up to 12-18g for anxiety
Divided doses with meals, Morning and evening
Myo-inositol powder
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
3-6 months
4-6 weeks
2-3 months
Initial use or high doses
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes
The Cochrane database of systematic reviews (2023) · Meta analysis · n=1319
For the primary neonatal outcomes, only one study measured the risk of a large-for-gestational-age infant and found myo-inositol was associated with both appreciable benefit and harm (RR 1.40, 95% CI 0.65 to 3.02; 1 study, 234 infants; low-certainty evidence).
Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nutrients (2022) · Meta analysis · n=1321
Pooled results were expressed as relative risk (RR) or mean difference (MD) with a 95% confidence interval (95% CI).
Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials
European review for medical and pharmacological sciences (2022) · Meta analysis · n=612
Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Based on multiple meta-analyses showing improved menstrual regularity and ovulation in PCOS. Evidence quality varies across studies with some showing minimal differences vs placebo. 4g daily most commonly studied dose.
AI-estimated from published studies. Interpret as directional guidance.
Myo-Inositol has a higher evidence score (7/10 vs 8.5/10) and wins in 2 of 3 categories.
No known interactions between Myo-Inositol and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.